Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email

Ultragenyx Pharmaceutical (RARE) News Today

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)
Free RARE Stock Alerts
$41.87
-0.74 (-1.74%)
(As of 05/17/2024 08:54 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability
May 19 at 5:39 AM | marketbeat.com
BNP Paribas Financial Markets Trims Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
BNP Paribas Financial Markets cut its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 26.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 157,281 shares of the biopharmace
May 17 at 4:30 PM | globenewswire.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2024 | markets.businessinsider.com
Buy Rating Affirmed: Ultragenyx’s Gene Therapy Shows Promising Efficacy and Safety Profiles
May 8, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
May 7, 2024 | finance.yahoo.com
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
May 6, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $109.00 at Canaccord Genuity Group
Canaccord Genuity Group cut their target price on Ultragenyx Pharmaceutical from $111.00 to $109.00 and set a "buy" rating for the company in a research note on Monday.
May 6, 2024 | marketbeat.com
New York State Common Retirement Fund Has $3.48 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
New York State Common Retirement Fund grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,866 shares of the biopharma
May 4, 2024 | finance.yahoo.com
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
May 4, 2024 | insidermonkey.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
May 4, 2024 | markets.businessinsider.com
Truist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
May 3, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)
May 3, 2024 | markets.businessinsider.com
Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)
May 3, 2024 | finance.yahoo.com
Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
May 3, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Misses Estimates By $0.31 EPS
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million for the quarter, compared to analysts' expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The firm's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.33) EPS.
May 3, 2024 | marketbeat.com
Cantor Fitzgerald Reiterates "Overweight" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Cantor Fitzgerald reiterated an "overweight" rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday.
May 3, 2024 | marketbeat.com
Wedbush Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $47.00
Wedbush cut their price target on Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a "neutral" rating for the company in a report on Friday.
May 2, 2024 | sfgate.com
Ultragenyx: Q1 Earnings Snapshot
May 2, 2024 | msn.com
Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64M
May 2, 2024 | investorplace.com
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
May 2, 2024 | globenewswire.com
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
April 30, 2024 | globenewswire.com
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
April 30, 2024 | markets.businessinsider.com
Ultragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline Potential
April 30, 2024 | finance.yahoo.com
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
April 27, 2024 | marketbeat.com
141,117 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by abrdn plc
abrdn plc bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 141,117 shares of the biopharmaceutical company's stock, valued at approximately $6,748,0
April 26, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on Thursday
Ultragenyx Pharmaceutical (NASDAQ:RARE) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.
April 25, 2024 | globenewswire.com
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
April 24, 2024 | nasdaq.com
First Week of RARE June 21st Options Trading
April 24, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $61.00 at TD Cowen
TD Cowen upped their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Wednesday.
April 23, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
April 22, 2024 | markets.businessinsider.com
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
April 22, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives New Coverage from Analysts at Royal Bank of Canada
Royal Bank of Canada initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Monday. They issued an "outperform" rating and a $77.00 price target on the stock.
April 19, 2024 | globenewswire.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2024 | marketbeat.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Federated Hermes Inc.
Federated Hermes Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,446,500 shares of the biopharmace
April 18, 2024 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
April 16, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 1.9%
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 1.9%
April 16, 2024 | marketbeat.com
Wedbush Reiterates Neutral Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Wedbush reiterated a "neutral" rating and issued a $48.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday.
April 16, 2024 | marketbeat.com
Mirae Asset Global Investments Co. Ltd. Has $5.18 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Mirae Asset Global Investments Co. Ltd. decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 48.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 108,355 share
April 15, 2024 | msn.com
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00
April 15, 2024 | markets.businessinsider.com
Ultragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick Facts
April 15, 2024 | finance.yahoo.com
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
April 12, 2024 | globenewswire.com
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
April 12, 2024 | finanznachrichten.de
Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
April 12, 2024 | globenewswire.com
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
April 11, 2024 | marketbeat.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Lessened by Peregrine Capital Management LLC
Peregrine Capital Management LLC decreased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 14.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,300 shares of the biopharmaceuti
April 9, 2024 | marketbeat.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine h
April 7, 2024 | cnn.com
Ultragenyx Pharmaceutical, Inc.
April 5, 2024 | markets.businessinsider.com
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
April 5, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 5.7%
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.7%
April 5, 2024 | marketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives "Overweight" Rating from Cantor Fitzgerald
Cantor Fitzgerald reaffirmed an "overweight" rating and set a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Elon to Transform U.S. Economy? (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

RARE Media Mentions By Week

RARE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RARE
News Sentiment
▼
1.01

0.42
▲
Average
Medical
News Sentiment

RARE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RARE Articles
This Week
▼
3

4
▲
RARE Articles
Average Week

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RARE) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Next President (Not Trump. Not Biden.)
The Freeport Society
Urgent Nvidia Warning
Altimetry
Elon’s New Device is About to Shock the World
InvestorPlace
"The Biggest Drug Ever" Is Coming
Behind the Markets
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders